IRIS
MENNA, PIERANTONIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 417
EU - Europa 224
AS - Asia 133
OC - Oceania 12
SA - Sud America 6
AF - Africa 1
Totale 793
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 405
GB - Regno Unito 82
SG - Singapore 80
CZ - Repubblica Ceca 54
DE - Germania 28
IT - Italia 28
IN - India 20
AU - Australia 12
CA - Canada 10
CN - Cina 10
FI - Finlandia 9
BE - Belgio 5
JP - Giappone 4
TW - Taiwan 4
FR - Francia 3
AL - Albania 2
AR - Argentina 2
BR - Brasile 2
CL - Cile 2
EE - Estonia 2
HK - Hong Kong 2
IE - Irlanda 2
PK - Pakistan 2
PL - Polonia 2
TR - Turchia 2
AE - Emirati Arabi Uniti 1
AT - Austria 1
BA - Bosnia-Erzegovina 1
BD - Bangladesh 1
BY - Bielorussia 1
DO - Repubblica Dominicana 1
ES - Italia 1
ID - Indonesia 1
IQ - Iraq 1
KR - Corea 1
KZ - Kazakistan 1
LK - Sri Lanka 1
MX - Messico 1
NL - Olanda 1
PH - Filippine 1
PT - Portogallo 1
RO - Romania 1
SA - Arabia Saudita 1
ZA - Sudafrica 1
Totale 793
Salva come PNG Salva come JPEG
Città #
Ashburn 121
Boardman 108
London 78
Singapore 60
Brno 35
Los Angeles 24
Rome 23
San Francisco 23
Redmond 20
Olomouc 17
Pune 17
Council Bluffs 16
Munich 12
Washington 10
Helsinki 9
Santa Clara 9
Seattle 9
Toronto 8
Melbourne 6
Haikou 4
Canberra 3
Hanover 3
Mol 3
Oklahoma City 3
Paris 3
Sydney 3
Taipei 3
Tokyo 3
Dublin 2
Hasselt 2
Lodz 2
New Delhi 2
North Liberty 2
Tallinn 2
Tirana 2
West Jordan 2
Almaty 1
Amsterdam 1
Ansan-si 1
Berlin 1
Buenos Aires 1
Central District 1
Centurion 1
Charlotte 1
Chicago 1
Clifton 1
Colombo 1
Columbia 1
Dhaka 1
Frankfurt am Main 1
Hicksville 1
Hradec Králové 1
Lisbon 1
Lomas de Zamora 1
Manila 1
Markham 1
Minsk 1
Naples 1
Nuremberg 1
Quilpué 1
Riyadh 1
Rockville 1
Sarajevo 1
Shanghai 1
Swansea 1
Vienna 1
Totale 679
Salva come PNG Salva come JPEG
Nome #
What is cardiotoxicity? 30
Anthracycline Cardiotoxicity 23
Early Diastolic Dysfunction after Cancer Chemotherapy: Primary Endpoint Results of a Multicenter Cardio-Oncology Study 23
Development and Validation of a UHPLC-MS/MS-Based Method to Quantify Cenobamate in Human Plasma Samples 18
Doxorubicin-Dependent Reduction of Ferrylmyoglobin and Inhibition of Lipid Peroxidation: Implications for Cardiotoxicity of Anticancer Anthracyclines 18
CARDIAC ANTHRACYCLINE ACCUMULATION AND B-TYPE NATRIURETIC PEPTIDE TO DEFINE RISK AND PREDICTORS OF CANCER TREATMENT RELATED EARLY DIASTOLIC DYSFUNCTION 17
Modeling human myocardium exposure to doxorubicin defines the risk of heart failure from low-dose doxorubicin 17
Anthracyclines 17
Paclitaxel and docetaxel enhance the metabolism of doxorubicin to toxic species in human myocardium 16
Pharmacokinetics of pegylated liposomal doxorubicin administered by intraoperative hyperthermic intraperitoneal chemotherapy to patients with advanced ovarian cancer and peritoneal carcinomatosis 16
Low level tumor necrosis factor-alpha protects cardiomyocytes against high level tumor necrosis factor-alpha: brief insight into a beneficial paradox 16
Oxidative degradation of cardiotoxic anticancer anthracyclines to phthalic acids. Novel function or ferrylmyoglobin 15
Pharmacology of Cardio-Oncology 15
NEW TARGETED DRUGS FOR ACUTE MYELOID LEUKEMIA AND ANTIFUNGALS: PHARMACOKINETIC CHALLENGES AND OPPORTUNITIES 14
From Cardiac Anthracycline Accumulation to Real-Life Risk for Early Diastolic Dysfunction: A Translational Approach 13
Beyond hypertension: Diastolic dysfunction associated with cancer treatment in the era of cardio-oncology 13
Anthracycline degradation in cardiomyocytes: a journey to oxidative survival 13
Further analytical, pharmacokinetic, and clinical observations on low-dose ponatinib in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia 13
Matters of the heart: The case of TNF-alpha targeting drugs. 13
Anthracyclines: molecular advances and pharmacological developments in antitumor activity and cardiotoxicity 13
Cardiotoxicity of targeted cancer drugs: concerns, “The cart before the horse,” and lessons from trastuzumab 13
Anthracycline Cardiotoxicity 13
Cardiovascular safety of anti-TNF-alpha therapies: Facts and unsettled issues. 12
The endogenous lusitropic and chronotropic agent, B-type natriuretic peptide, limits cardiac troponin release in cancer patients with an early impairment of myocardial relaxation induced by anthracyclines 12
The concomitant management of cancer therapy and cardiac therapy 12
Altered iron regulatory protein activities in doxorubicin-treated cardiomyocytes : Distinct roles of reactive oxygen species and of the secondary alcohol metabolite doxorubicinol 12
4’- Epidoxorubicin to reexplore anthracycline degradation in cardiomyocytes 11
Cardio-oncology in clinical studies and real life 11
Pharmacology of cardio-oncology: chronotropic and lusitropic effects of B-type natriuretic peptide in cancer patients with early diastolic dysfunction induced by anthracycline or nonanthracycline chemotherapy 10
Cancer drugs and QT prolongation: weighing risk against benefit 10
Impairment of myocardial contractility by anticancer anthracyclines: role of secondary alcohol metabolites and evidence of reduced toxicity by a novel disaccharide analogue 10
Cardiotoxicity of antitumor drugs 10
Taxanes stimolate Doxorubicin conversion to its cardiotoxic secondary alcohol metabolite doxorubicinol: studies in human myocardium 10
Pharmacology of Ranolazine versus Common Cardiovascular Drugs in Patients with Early Diastolic Dysfunction Induced by Anthracyclines or Nonanthracycline Chemotherapeutics: A Phase 2b Minitrial 10
Safety and tolerability of a novel oral nutritional supplement in healthy volunteers 10
Ibrutinib and Bruton's tyrosine kinase inhibitors in chronic lymphocytic leukemia: focus on atrial fibrillation and ventricular tachyarrhythmias/sudden cardiac death 10
Doxorubicin degradation in cardiomyocytes 9
Pharmacokinetic characterization of amrubicin cardiac safety in an ex vivo human myocardial strip model I Amrubicin accumulates to a lower level than doxorubicin or epirubicin 9
Managing anthracycline-induced cardiotoxicity: beginning with the end in mind 9
In ®Entresto we trust 9
An introduction to the metabolic determinants of anthracycline cardiotoxicity 9
The novel anthracycline MEN 10755 is less cardiotoxic than doxorubicin or epirubicin due to reduced formation and aconitase-reactivity its secondary alcohol metabolite 9
Doxorubicin irreversibly inactivates Iron Regulatory Proteins 1 and 2 in cardiomyocytes : Evidence for distinct metabolic pathways and implications for iron-mediated cardiotoxicity of antitumor therapy 9
Choosing Antifungals for the Midostaurin-Treated Patient: Does CYP3A4 Outweigh Recommendations? A Brief Insight from Real Life 9
Paclitaxel and docetaxel stimulation of doxorubicinol formation in the human heart: Implications for cardiotoxicity of doxorubicin-taxane chemotherapies 8
Role of secondary alcohol metabolites in anthracycline cardiotoxicity: from hypotheses to new drugs 8
Tumour necrosis factor alpha (TNFα)cardiomyocyte preconditioning: clues to explain anti-TNFα agents contraindication in severe heart failure 8
Isavuconazole: case report and pharmacokinetic considerations 8
Doxorubicinolone formation and efflux : A salvage pathway against epirubicin accumulation in human heart 8
Paclitaxel and docetaxel stimulation of doxorubicinol formation in the human heart: Implication for cardiotoxicity of doxorubicin-taxane chemotherapies 8
Defective taxane stimulation of epirubicinol formation in the human heart: Insights into the cardiac tolerability of epirubicin-taxane chemotherapies 8
Anthracycline metabolism and toxicity in human myocardyum: Comparisons between doxorubicin, epirubicin, and a novel disaccaride analogue with redeced formation and [4Fe-4S]-reactivity of its secondary alchol metabolite 8
MEN 10755 : A novel disaccharide anthracycline with a reduced level of formation and [4Fe-4S]-reactivity of toxic alcohol metabolite in human heart . 8
Cardiovascular toxicity of antitumor drugs :Translating molecular mechanisms into clinical facts 8
MEN 10755: a novel disaccaride anthracycline with a reduced level of formation and [4Fe-4S]- reactivity of toxic alcohol metabolite in human myocardium 8
Doxorubicin dependent reduction of hypervalent ferrylmyoglobin: One more evidence against the oxidative nature of doxorubicin-induced cardiotoxicity 8
Defective one or two electron reduction of the anticancer anthracycline epirubicin in human heart: Relative importance of vesicular sequestration and impaired efficiency of electron addition 8
Anthracyclines and Cardiotoxicity: Is CARP a Forgotten Biomarker? 7
Recommendations for the harmonization of reference intervals in the therapeutic monitoring of antiepileptic drugs|Indicazioni per l’armonizzazione degli intervalli di riferimento nel monitoraggio terapeutico di farmaci antiepilettici 7
Pharmacological Foundation of Cardio-Oncology 7
Do you know pixantrone? 7
Defective one or two electron reduction of the anticancer anthracycline epirubicin in human heart: relative importance of vesicular sequestration and impaired efficiency of electron addition J. Biol. Chem 7
Modified colistin regimen for critically ill patients with acute renal impairment and continuous renal replacement therapy 7
Pharmacokinetic characterization of amrubicin cardiac safety in an ex vivo human myocardial strip model II. Amrubicin shows metabolic advantages over doxorubicin and epirubicin 7
Doxorubicin Cardiotoxicity and the Control of Iron Metabolism: Quinone-Dependent and Independent Mechanisms 7
Doxorubicin metabolism to toxic species in human myocardium: stimulation by paclitaxel and docetaxel but not BMS 184476 or BMS 188797 7
Chronic cardiotoxicity of anticancer anthracyclines in the rat: role of secondary metabolites and reduced toxicity by a novel anthracycline with impaired metabolite formation and reactivity 7
Correction: Infectious complications of targeted drugs and biotherapies in acute leukemia. Clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL), a joint venture of the European Group for Blood and Marrow Transplantation (EBMT), the European Organization for Research and Treatment of Cancer (EORTC), the International Immunocompromised Host Society (ICHS) and the European Leukemia Net (ELN) 7
Quantitative Analysis of Cenobamate and Concomitant Anti-Seizure Medications in Human Plasma via Ultra-High Performance Liquid Chromatography–Tandem Mass Spectrometry 7
The novel anthracenedione, pixantrone, lacks redox activity and inhibits doxorubicinol formation in human myocardium: Insight to explain the cardiac safety of pixantrone in doxorubicin treated patients 6
Low dose anthracycline and risk of heart failure in a pharmacokinetic model of human myocardium exposure: analog specificity and role of secondary alcohol metabolites 6
In vitro modelling of the structure-activity determinants of anthracycline cardiotoxicity. 6
Rethinking drugs from chemistry to therapeutic opportunities: Pixantrone beyond Anthracyclines. 6
Pixantrone (PIX) Inhibition of Doxorubicinol (DOXOL) Formation in Human Myocardium: Implications for Cardiac Safety in Non-Hodgkin Lymphoma (NHL) Patients with Prior Anthracycline Treatment 6
Tnf-alpha induced cardioprotection: effects on reactive oxygen species (ros) and apoptosis 6
Posaconazole and midostaurin in patients with FLT3-mutated acute myeloid leukemia: Pharmacokinetic interactions and clinical facts in a real life study 5
The reality of pixantrone in real life 5
Telaprevir raises the plasma/whole blood ribavirin ratio: trying to come full circle on a dangerous relationship 5
Tumor necrosis factor alpha and cardiomyocytes: evidence for a self-protective preconditioning 5
Ferrylmyoglobin-dependent oxidative degradation of doxorubicin: a novel pathway of anthracycline metabolism and toxicity 5
Minimal sampling colistin pharmacokinetics in critically ill patients 5
Molecular determinants of the reduced cardiotoxicity of epirubicin 5
Primary prevention strategies for anthracycline cardiotoxicity: a brief overview 4
Efficacy and safety of low dose ponatinib in a case of Ph-positive acute lymphoblastic leukaemia 4
Translating molecular mechanisms into clinical facts 4
The use of pegylated liposomal doxorubicin with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients undergoing cytoreductive surgery (CS) for peritoneal carcinomatosis of ovarian origin 4
Doxorubicin inhibits ferrylmyoglobin-dependent lipid peroxidation 4
High Incidence of Invasive Fungal Diseases in Patients with FLT3-Mutated AML Treated with Midostaurin: Results of a Multicenter Observational SEIFEM Study 4
Anthracyclines, diastolic dysfunction and the road to heart failure in Cancer survivors: An untold story 3
Increasing doxorubicin antitumor activity through COX-2 inhibition without increasing cardiotoxicity 3
Taxanes stimulate doxorubicin conversion to its cardiotoxic secondary alcohol metabolite : Studies in human myocardium. 3
Predictors of early or delayed diastolic dysfunction after anthracycline-based or nonanthracycline chemotherapy: a pharmacological appraisal 2
Infectious complications of targeted drugs and biotherapies in acute leukemia. Clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL), a joint venture of the European Group for Blood and Marrow Transplantation (EBMT), the European Organization for Research and Treatment of Cancer (EORTC), the International Immunocompromised Host Society (ICHS) and the European Leukemia Net (ELN) 2
Totale 877
Salva come PNG Salva come JPEG
Categoria #
all - tutte 23.541
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 23.541
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022219 0 4 0 0 0 0 1 92 4 0 5 113
2022/202356 2 1 1 4 2 2 15 0 3 3 22 1
2023/2024337 6 36 11 16 37 148 1 16 2 8 4 52
2024/2025265 103 37 124 1 0 0 0 0 0 0 0 0
Totale 877